continue to be the main contributors to accidental deaths involving opioids. Although small compared with American data, the experience in Australia has been similar to that in the US, with the data indicating a rise in harm driven by a range of factors, including unrealistic expectations of pain management, inappropriate prescribing and lack of evidence-based educational programs for health professionals. 2, 3 Initiating opioid therapy in a hospital setting has been identified as a key risk for ongoing use. 4 Opioids are commonly prescribed to treat postsurgical pain. 5 With more than 2.2 million surgeries in Australia in 2016-17, 6 this has substantial implications for the treatment of pain in a hospital setting. A systematic review has indicated that one-third of adults receiving longterm opioid therapy received their first opioid prescription from a surgeon, highlighting that postsurgical prescribing in hospitals is an important point of intervention. 7 The dose and quantities of opioids prescribed at discharge have been identified as a risk factor for long-term use, 8 with each refill or an additional week of supply being associated with a 44% increase in the rate of misuse. 9 In addition, the potential risk of harm is considerably higher with sustained-release opioids compared with immediate-release opioids. 10 Hence, it is increasingly accepted that the risk of opioid harm results from a combination of dose, duration, quantity, surgical procedure and patient risk factors. 4, 11 Hospital pharmacists are well placed to influence this nexus of patient care through their work in opioid stewardship, on surgical wards and in medicines management at discharge. There has been increasing concern by pharmacists and other healthcare practitioners that practices in hospitals were variable and that strategies to reduce potential harms need to be widely adopted. The Society of Hospital Pharmacists of Australia (SHPA) undertook a survey of Australian hospitals with the aim of identifying existing practices in Australian hospitals relating to opioid prescribing and dispensing for patients undergoing surgery in order to inform conversations with stakeholders, and advocacy with government, as well as to identify priorities for reducing harm to patients. The full report is available at www.shpa.org.au/advocacy. publication as a special report at the request of the Editor, drawing out elements of the full report of most relevance to those working in clinical pharmacy services. This paper reports the results of an online survey of hospital pharmacists working in public and private hospitals, informed by 135 Australian hospital facilities, regarding pharmacy service provision, workload, prescribing practice and dispensing activities. While providing valuable insights, the results cannot be considered to represent all hospitals or hospital pharmacies in Australia.
The survey questions and methodology were developed and reviewed by the Opioid Advocacy Working Group, consisting of SHPA Branch representatives, subject matter experts and the SHPA advocacy team. The survey was conducted in May 2018 using SurveyMonkey over two weeks and targeted at Directors of Pharmacy and their delegates via email and SHPA eNews. Survey respondents were advised to complete separate surveys for each site providing surgical services within a network, given that it is widely accepted that practices and service provision can vary significantly. All responses were anonymous. In all, 170 responses were received, of which 135 completed more than 55% of the survey and were included in the analysis. The responses were analysed by an independent researcher to avoid reporting bias.
Following the survey, selected SHPA members were invited to join stakeholders at a Medicines Leadership Forum in July 2018 where the results were presented. Participants were divided into four streams (Managing Medication Supply, Empowering Patients, Working with Prescribers, and Supporting Transitions of Care) to discuss the findings and recommendations. These discussions informed the development of final key recommendations.
DEMOGRAPHICS
In the reported results there was proportionate national representation with a slightly higher representation from Victorian hospitals, reflective of SHPA membership. Forty per cent of 135 responses were from Victoria, whereas 19% were from New South Wales, 15% were from Queensland, 11% were from Western Australia, 8% were from South Australia, 3% were from the Australian Capital Territory, 2% were from Tasmania and 2% were from the Northern Territory. Geographically, there was diverse representation from hospital sites in metropolitan and non-metropolitan areas, with 59% of hospitals from metropolitan regions, 30% in regional areas and 11% in rural areas. 
KEY FINDINGS AND IMPLICATIONS
It is accepted that whenever and wherever Australians are receiving healthcare that the care should be safe and of high-quality. This is the fundamental cornerstone of the Australian Charter of Healthcare Rights. 12 The key findings indicate that variations in practice in hospitals affect the care provided to surgical patients who are at risk of opioid-related harm. This is detailed in the following sections.
Six specific themes were identified: Working with Prescribers, Engaging Patients, Managing Medication Supply, Supporting Opioid Stewardship, Supporting Transitions of Care, and Empowering Pharmacists.
Thirty-three recommendations were developed (Table 1) .
Key findings identified that sizeable gaps exist in the provision by pharmacists of medication reconciliation, clinical review of patients and risk factors and review of postsurgical analgesic use. Provision of pain services and stewardship also varied significantly.
Clinical pharmacy capacity at hospitals with substantial surgical patient loads is variable, especially in private hospitals and in regional or rural locations. In some locations, medication management services for patients prior to and after surgery are not proportionate to their pharmacy care requirements, and do not meet accepted standards of practice.
Relatedly, risk factors for opioid harm are not commonly prioritised by contemporary clinical pharmacy tools and screening that direct which admitted patients receive pharmacy care. As reported by respondents, pharmacists frequently prioritise the risk of short-term harm (or rehospitalisation) related to medical complications, chronic conditions or extremely high-risk medicines rather than the long-term risk of opioid misuse and dependence to allocate resources relating to clinical pharmacy services, counselling, provision of discharge information and supply. The provision of pharmacy services related to reducing medicine-related harm was during admission and at discharge. 3. Support the widespread use of data from real-time prescription monitoring systems to optimise patient safety and inform prescribing and dispensing of opioids in hospitals. 4. Advocate for the widespread adoption of digital solutions that enable reporting of data on prescribing and dispensing for use in the education of medical, nursing and pharmacy staff. 5. Provide feedback on prescribing patterns based on this reporting to inform systematic education of medical officers and multidisciplinary teams, and produce education to support hospital pharmacists working in areas of medication safety, stewardship and clinical pharmacy. 6. Support greater recognition of the role of pharmacists to work within multidisciplinary teams to inform decision making regarding appropriate pain management and establish patient-centred opioid de-escalation management plans. 7. Share existing pharmacy resources proactively to enable greater collaboration and less duplication of clinician effort in reducing opioid harm. 8. Support the development of a case study of the South Australian governance-led model for analgesic prescribing and dispensing for reference and consideration by other healthcare providers.
Engaging patients 9. Support greater health literacy by replacing language using 'painkillers' with 'medicines for reducing pain' to reduce confusion and manage expectations among patients. 10. Support the development of patient-centred tools for self-assessment and management to reset community expectations of pain and the use of medicines for reducing pain, and advise on the proper disposal of opioids to reduce diversion and inappropriate use. 11. Advocate for national education campaigns that aim to reset community expectations of pain and the use of medicines for reducing pain, and advise on the proper disposal of opioids to reduce diversion and inappropriate use. 12. Support consumer health organisations to educate patients regarding managing expectations regarding pain with healthcare providers as appropriate. 13. Disseminate Choosing Wisely Australia principles to prompt conversations with patients regarding opioid-related harm.
Supporting opioid stewardship 14. Advocate for the implementation of opioid stewardship programs in public and private hospitals nationally. 15. Create a toolkit to support clinicians wanting to implement an opioid stewardship program in their health service. 16 . Advocate for the specific inclusion of opioid stewardship in relevant healthcare standards, including National Safety and Quality Health Standard 4: Medication Safety, as done for antimicrobial stewardship in the Preventing and Controlling Healthcare Associated-Infection Standard. 17. Consider the specific requirements of opioid stewardship programs for distinct patient groups that may not be captured in standard opioid stewardship programs (e.g. paediatric and obstetric patients).
Managing medication supply 18. Encourage pharmaceutical manufacturers to produce greater variety in opioid pack sizes (i.e. packs of 5, 10 and 20 tablets). 19. Advocate for clinicians to be supported to prescribe the smallest quantity of analgesics, including dispensing partial packs where this is appropriate for the needs of the patient. 20. Advocate to government and regulatory authorities for increased information on opioid labelling relating to the risk of long-term use and overdose. 21. Advocate for the creation of a National Opioid Utilisation Surveillance Program (similar to the National Antimicrobial Utilisation Surveillance Program funded by the ACSQHC) for hospitals to monitor opioid usage rates and enable benchmarking with similarly peered hospitals to identify areas for improvement. 22. Encourage hospitals to review both medicines formulary and governance systems to ensure hospital systems minimise the risk of misuse among patients. 23. Encourage hospital pharmacies to review EMR management, dispensing and prescribing software systems to identify any unintended design features that affect incidence, quantity or duration of opioid supply (i.e. order sets that include opioids, autopopulated dosing regimens and automatic quantities including PBS quantities, use of continue supply tick boxes etc.).
reported to be significantly lacking for day surgery patients.
Reporting of the use of sustained-release opioids in the treatment of acute pain for surgical patients during admission and at discharge was very high. Current discharge practices, as reported, result in opioid quantities in excess of patient need being provided, which have the potential to lead to preventable harm.
Information provided by hospital pharmacists regarding patient care (including medication lists, discharge summaries and pain management plans) at discharge is inconsistent, indicating many patients and their general practitioners (GPs) are not receiving the appropriate information to best manage opioid and analgesic therapy for patients recovering from surgery.
Despite widespread interest, implementation of innovative pharmacy practices, such as the introduction of pharmacy-led opioid stewardship services, are not emerging at a rate likely to reduce patient risk in the near future.
SERVICE PROVISION Provision of Opioid Stewardship Programs
Less than 5% of respondents indicated that their hospitals had a formal opioid stewardship program, whereas 13% reported a limited program (Figure 1) . Combined, this indicates that less than one-fifth of hospitals have some form of hospital-wide opioid stewardship model in place.
The hospitals providing either a formal or informal opioid stewardship service were more concentrated in the principal referral and acute A/B hospital categories. Regardless of whether an existing service operated, respondents across all hospital types and settings were overwhelmingly (nearly 95%) supportive of opioid stewardship programs being expanded, reporting their existing services were insufficient to meet patient demand.
Hospitals with formal opioid stewardship services were more likely to have reviewed and documented prior opioid use during medication reconciliation. At discharge, they were more likely to have reviewed the past 48 h of analgesic use to determine appropriate quantity, and ensured patients being supplied opioid analgesics were always or often provided counselling by a pharmacist. 25. Encourage hospitals to implement a KPI ensuring every patient prescribed analgesic medicine at discharge has a multidisciplinary pain management plan. 26. Support the inclusion of pharmacists in the completion of hospital discharge summaries for patients leaving the hospital. Opioid stewardship addresses the prevention of inappropriate opioid prescribing and supply, among other quality and safety activities. As an emerging model, it is not surprising that the prevalence of opioid stewardship services is currently extremely low, but it is concerning that the barriers reported to introducing the service were numerous, with the most common ones being lack of jurisdictional funding, support from hospital management and pharmacy staff with expertise. The final report of the 2018 Victorian Inquiry into Drug Law Reform recommended a sector-wide trial based on an opioid stewardship model be implemented to promote and audit best practice regarding the prescribing and use of medicines with potential for misuse. 13 Other states, including Queensland and Western Australia, have also trialled variations of opioid stewardship.
Empowering pharmacists

PATIENT JOURNEY Pharmacy Service at Admission
Survey results highlight variance existing in the provision and consistency of a pharmacist-led medication reconciliation. Thirty-seven per cent of respondents reported that prior opioid use was discussed with 'some' patients as part of medication reconciliation ( Figure 2 ). Nine per cent reported medication reconciliation was provided by non-pharmacists. Provision of medication reconciliation specifically for surgical patients was not specified. These findings indicate that a safety and quality risk may be present for patients where first review is delayed during their hospital stay or additional pharmacy review is not provided. High patient turnover in the surgical setting provides further challenges in proving pharmacist services for medication reconciliation.
Access to Clinical Pharmacy Services
Most responding pharmacists were expected to prioritise high-risk patients for clinical pharmacy services (53%) rather than having capacity to provide clinical services for all patients (32%), indicating that pharmacist resourcing impacts medicine management services resulting in inequity of patient review ( Figure 3 ). Priority was reportedly given to patients with multiple chronic conditions or comorbidities (65%), age (59%), concurrent anticoagulant use (55%) and renal or hepatic impairment (47%; Figure 4 ). Often consideration was given to screening tools or referrals from nursing or medical staff. Twenty-four per cent of respondents indicated that a patient already taking opioids prior to admission would be prioritised for clinical pharmacy services, with 17% of respondents prioritising patients with known opioid tolerance. Opioid-na€ ıve patients were only considered for prioritisation by 9% of respondents. not been adapted to reflect the risk of initiating opioid use in opioid-na€ ıve patients.
According to the SHPA Standard for Clinical Pharmacy Services, 14 patients receiving a high-risk medicine should be prioritised for clinical pharmacy services. The stratifying of patient risk to determine patient care is common in health care and relatively sound, but the results of the survey indicate that gaps in pharmacy services exist that exclude patients from appropriate care. The sheer level of demand and complexity of patient needs in an acute setting may contribute to patients with uncomplicated surgical outcomes receiving lower priority. However, it is known that the simplicity of a surgical procedure from a clinician's perspective does not correlate to a lower risk of opioid harm. 15 
USE OF MEDICINES Commonly Prescribed Analgesics for Opioid-Na€ ıve Patients at Admission and Discharge
When treating acute pain in opioid-na€ ıve patients, respondents reported that hospital prescribers commonly prescribed (in order of prevalence) immediaterelease opioids (97%), non-opioid analgesics (96%), sustained-release opioids (oral formulations; 77%) and partial or mixed opioids (74%; Figure 5 ).
It would be reasonable to expect differences in prescribing during discharge in opioid-na€ ıve patients as opposed to admission, with recovery from surgery tending to lessen the need for opioids. However, reported trends of supply during discharge were very similar to admission: immediate-release opioids (97% vs 97%, respectively), non-opioid analgesic (97% vs 96%, respectively), sustained-release opioids (oral formulation; 71% vs 77%, respectively) and partial/mixed opioids (66% vs 74%, respectively).
The high rate of sustained-release opioids reported to be commonly prescribed for the treatment of acute pain is a concern, because this has the potential to initiate unintended ongoing use. 8 The Australian and New
Zealand College of Anaesthetists (ANZCA) Faculty of Pain Management 2018 statement specifically mentions sustained-release options are associated with a high risk of harm for first-time users, the elderly and people on other medications. 10 It is of note that South Australia consistently reported sustained-release opioids as less commonly prescribed compared to the national average ( Figure 6 ). More than 70% of respondents nationally reported sustainedrelease opioids as standard treatment for inpatients and at discharge (77% and 70%, respectively), compared with 20% and 10%, respectively, in South Australia. Prescribing immediate-release opioids for inpatients and at discharge was consistent nationally. Further analysis is required to assess the reason for these results, but anecdotal feedback indicates that South Australia's adoption of a state-wide formulary process and centralised governance function which specifically restrict supply of sustained-release opioids for patients with acute pain may have contributed. Given the risk of harm is considerably higher with sustained-release opioids than immediate-release opioids, 10 this formulary-driven practice merits great interest.
Review of Medicine Use by Patients After Surgery
According to the survey results, substantial variances exist in pharmacist interventions ensuring postsurgical patients have their medicines reviewed before discharge, with less than one-quarter of respondents (23%) 'always' reviewing a patient's analgesic medicine use in the 48 h prior to discharge to inform appropriate prescribing. Slightly more hospitals (31%) reported that pharmacists completed a review 'often', whereas 28% 'sometimes' completed a review (Figure 7) . A minority (13%) of respondents indicated that a pharmacist 'rarely' or 'never' reviewed the last 48 h of analgesic use prior to discharge. Through comments, respondents from private and public facilities indicated patients in day surgery were not in hospital long enough for this review to occur and that their day surgery units were often not supported by a hospital pharmacist. SHPA recommendations for clinical pharmacy services for same-day admissions in both public and private facilities is one full-time equivalent (FTE) for every 22 beds. 14 Respondents reported that even when patients' pain had not required opioid analgesic in the 48 h prior to discharge, more than 70% still supplied opioids more often than not to take home 'just in case' (Figure 8 ). Several comments indicated that the amount supplied depended on factors such as patient expectations, the prescriber and, on occasion, the confidence of the pharmacist. A recent coroner's report described pharmacists as having 'a vital failsafe role in preventing inappropriate prescribed medication from reaching patients'. 16 
Patient Counselling and Information About Medicine Use
Counselling patients on the risks of a medicine, short and long term, is a fundamental expectation of patients and core to a pharmacist's role, but provision of counselling regarding opioids for patients after surgery was inconsistent. Although 39% of respondents indicated that patients would 'always' receive counselling on opioids upon discharge after surgery, this leaves a significant number of patients at risk of not receiving counselling for a high-risk medicine at discharge. The survey findings indicated that patients undergoing day surgery were at most risk of missing out on counselling. Fourteen per cent of respondents across public and private hospitals 'always' provided counselling for this cohort. This is potentially due to an assumption that sameday surgeries are less surgically complex and thus require fewer clinical services upon discharge, but this does not correlate with a reduced risk of misuse. 16 Twenty per cent of respondents at private hospitals reported a pharmacist did not provide counselling on medicines to patients at discharge. In 2016, 67% of surgery undertaken in Australia occurred in a private hospital. 6 
TRANSITION OF CARE
Information Provided to Patient's GP or Community Care Provider After Discharge
The findings indicated a strong commitment to providing an updated medicines list (74%). Forty-six per cent of respondents reported that they provide a discharge summary either to the patient or to their GP or community pharmacist ( Figure 9 ). However, additional comments indicated this was often only for 'high-risk' patients, which highlights that many patients leaving hospitals (including surgical patients) would not have a discharge summary provided. Although it is possible that this task is undertaken by others in the multidisciplinary team, variance in the provision of this information is well recognised as a key gap in care. Equally concerning is the absence of management plans, such as pain management plans and opioid de-escalation plans, reported to not be provided by 90% of respondents, which would otherwise be of assistance to GPs and community pharmacists. The transition of patients from hospital to the community remains a key vulnerability for medicine management, with more than 50% of medication errors occurring at transitions of care. 17 The limited capacity of pharmacists to provide medication management plans in discharge summaries for all patients has safety implications, given the higher quality of pharmacist-completed medication management plans in discharge summaries 18 and their importance in ensuring continuing high-quality care.
CONCLUSION
As medicines experts working in an acute setting, hospital pharmacists have a key role as a safeguard to reduce the risk of inappropriate medicine prescription, supply and use. Pharmacists also have a regulatory obligation to optimise medicine management and medicine safety for patients. SHPA's key findings indicate that variations in practice in hospitals affect the care provided to surgical patients who are at risk of opioid-related harm. To address this, a range of innovative strategies that enable improved patient care alongside prescriber and governance support (including opioid stewardship) should be considered for expansion. This could be coordinated alongside current interventions in the primary care sector, such correspondence to outlier community prescribers from Australia's Chief Medical Officer, but, to date, the role of hospitals as potentially the site of initial opioid prescription appears unrecognised.
This work provides an insight into current hospital and pharmacy practices and identifies areas for improvement and innovation for reducing opioid harms, as outlined in the recommendations. SHPA and our members remain committed to supporting further discussions with stakeholders, including other health practitioners and hospital managers, regarding service provision, clinical care and governance in an effort to mitigate this risk for Australian patients.
